News
R&D
-
Group Company
R&D
August 1, 2023
-
Notification of Approval to Manufacture and Market Nanozora® 30mg Autoinjectors for S.C. Injection in Japan
-
Group Company
R&D
September 28, 2022
-
Notification of Application for Approval to Manufacture and Market Rheumatoid Arthritis Therapy Nanozora® 30mg Autoinjectors for S.C. Injection in Japan
-
Group Company
R&D
September 26, 2022
-
Notification of Approval to Manufacture and Market Nanozora® 30mg Syringes for S.C. Injection, a Therapy for Rheumatoid Arthritis, in Japan Japan's First NANOBODY® Therapeutic
-
Group Company
R&D
August 5, 2022
-
Cetylpyridinium chloride hydrate (CPC) confirmed to have an action of inactivating SARS-CoV-2 variants
-
Group Company
R&D
December 20, 2021
-
Data from Japan's First Phase II/III Clinical Trial of NANOBODY® Ozoralizumab for Rheumatoid Arthritis Presented at the 36th Annual Meeting of the Japanese Society for Clinical Rheumatology and Related Research
-
Group Company
R&D
October 25, 2021
-
Cetylpyridinium chloride hydrate (CPC) confirmed to have an action inactivating SARS-CoV-2
-
Group Company
R&D
March 22, 2021
-
Notification of Application for Approval to Manufacture and Market Anti-TNFα multivalent NANOBODY® compound (ozoralizumab) in Japan
Japan's first NANOBODY® Therapeutic
-
Group Company
R&D
February 22, 2021
-
Notification of Application for Approval of Manufacturing and Marketing for Orally Disintegrating Films of SGLT2 Inhibitor Lusefi® Tablets
-
Group Company
R&D
April 30, 2020
-
Taisho and BioAge sign exclusive license agreement for the development, manufacturing, and commercialization of hypoxia inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, TS-143, worldwide
-
Group Company
R&D
October 1, 2019
-
Taisho and Moberg Pharma sign exclusive license agreement for the development and commercialization of MOB-015 in Japan
